VSTM — Verastem, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1526119 ·
Last close
$7.41
Market Cap
$933.77M
52W High
$10.82
52W Low
$3.43
ADV30
4,823,134
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 24,012,000 20,067,000 -75,224,000 -74,723,000 229,637,000 172,801,000 219,536,000
Jun 2026 40,078,000 36,037,000 -32,710,000 -34,673,000 206,511,000 136,353,000 156,525,000
Mar 2026 18,671,000 15,620,000 -44,897,000 -36,591,000 227,808,000 165,551,000 146,031,000
Dec 2025 17,535,000 14,643,000 -41,475,000 -32,916,000 246,442,000 204,990,000 189,245,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-162,195,000
Investing CF
$-9,389,000
Financing CF
$143,615,000
CapEx
$-1,345,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,236,262,000
Inventory
$2,396,000
Receivables
$29,074,000
ST Investments
$16,127,000
EBIT TTM
$-200,406,000
Pretax Income TTM
$-201,882,000
Interest Exp TTM
$1,476,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$100,296,000
EBITDA
$-193,170,000
Free Cash Flow
$-92,652,496
Enterprise Value
$1,015,544,512
Total Cash
$172,800,992
Total Debt
$128,561,000
Shares Out
126,014,804
Trailing EPS
$-1.84
Book Value
$0.11
ROE
-471.2%
ROA
-59.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 30,914,000 -170,129,000 -209,471,000 246,442,000 189,245,000 57,197,000 -137,509,000
Dec 2024 10,000,000 -114,956,000 -130,637,000 101,538,000 130,431,000 -28,893,000 -104,771,000
Dec 2023 0 -92,084,000 -87,367,000 149,718,000 92,344,000 57,374,000 -86,460,000
Dec 2022 2,596,000 -72,937,000 -73,812,000 95,050,000 47,659,000 47,391,000 -63,673,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$86,566,000
NetIncome TTM
$-202,698,000
OpCashFlow TTM
—
Assets (Latest)
$206,511,000
Forward EPS
$-1.22

Max Pain — expiry 2027-01-15

max pain strike: $6.00 · spot: $6.87 · call oi: 6,210 · put oi: 1,460
Expected Move to 2027-01-15: ±$2.12 (30.93%) — implied range $4.74 – $8.99 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LTGO Latigo Biotherapeutics, Inc. $912.28M $13.76 —
MLTX MoonLake Immunotherapeutics $957.45M $11.25 —
SPTX Seaport Therapeutics, Inc. $972.65M $18.17 —
JBIO Jade Biosciences, Inc. $979.40M $15.40 —
SVRA Savara Inc $988.39M $4.48 —

News headlines (Yahoo Finance, 1h cache)

Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer
2026-11-18 14:00 · Yahoo
Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
2026-11-16 19:13 · Yahoo
Verastem Stock In Focus After Earnings Update And New Financing Plans
2026-11-13 02:14 · Yahoo
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
2026-11-11 14:13 · Yahoo
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
2026-11-10 07:12 · Yahoo
What Verastem (VSTM) Said on Its Q3 Earnings Call
2026-11-07 00:14 · Yahoo
Verastem (VSTM) Q3 2026 Earnings Call Transcript
2026-11-06 23:50 · Yahoo
Verastem (VSTM) Wins FDA Priority Review, Is The Stock Cheap Or Priced For More?
2026-11-06 21:12 · Yahoo
Verastem, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Verastem Inc (VSTM) Q3 2026 Earnings Call Highlights: Avmapki Revenue Surges 114% as VS-7375 ...
2026-11-06 09:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.